2403 related articles for article (PubMed ID: 27044767)
21. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.
Ye JZ; Zhang YQ; Ye HH; Bai T; Ma L; Xiang BD; Li LQ
World J Gastroenterol; 2014 Dec; 20(45):17141-7. PubMed ID: 25493028
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].
Zhao M; Wang JP; Li W; Huang ZL; Zhang FJ; Fan WJ; Zhang L; Li XS; Pan CC; Wu PH
Zhonghua Yi Xue Za Zhi; 2011 May; 91(17):1167-72. PubMed ID: 21756768
[TBL] [Abstract][Full Text] [Related]
23. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
25. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY
PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
27. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study.
Long J; Zheng JS; Sun B; Lu N
Hepatol Int; 2016 Jan; 10(1):175-84. PubMed ID: 26742761
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
29. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
30. [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Chen JW; Pang PF; Meng XC; Zhou B; Huang WS; Guo YJ; Zhu KS; Shan H
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(9):663-7. PubMed ID: 23751743
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
32. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
[TBL] [Abstract][Full Text] [Related]
34. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
Mähringer-Kunz A; Steinle V; Kloeckner R; Schotten S; Hahn F; Schmidtmann I; Hinrichs JB; Düber C; Galle PR; Lang H; Weinmann A
PLoS One; 2021; 16(5):e0249426. PubMed ID: 33961627
[TBL] [Abstract][Full Text] [Related]
35. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
Yuan J; Yin X; Tang B; Ma H; Zhang L; Li L; Chen R; Xie X; Ren Z
Biomed Res Int; 2019; 2019():2141859. PubMed ID: 31467872
[TBL] [Abstract][Full Text] [Related]
37. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus.
Zheng N; Wei X; Zhang D; Chai W; Che M; Wang J; Du B
Medicine (Baltimore); 2016 Jun; 95(26):e3959. PubMed ID: 27367992
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
39. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
